Clinical effect of pharmaceutical products using communication tool integrated with compound of several pharmaceutical products

Abstract

A method of treating a medical condition with a combination of substances, wherein one of the substances is adalimumab, in combination with a computer program configured for: providing a patient with sets of questions adapted to the combination, to adalimumab, and to the non-adalimumab substances, wherein at least one of the sets of questions is related to perceived and / or measured therapeutic effects; subjecting the answers to the sets of questions to functions, thereby generating patient specific feedback; and adjusting a dosage of at least one substance based at least in part on the patient-specific feedback.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. Ser. No. 16 / 160,519 filed Oct. 15, 2018 which was a continuation of U.S. Ser. No. 14 / 417,265 filed Jan. 26, 2015, which was a national stage application, filed under 35 U.S.C. § 371, of International Patent Application No. PCT / SE2013 / 050896 filed Jul. 12, 2013, which claims priority to SE application No. 125089-3 filed Jul. 24, 2012. Each of the previously noted applications is hereby incorporated by reference in their entirety.FIELD OF THE INVENTION[0002]The present invention relates to the field of improving the usage and clinical efficacy of pharmaceutical products in clinical practice, improving health situation of patients, where a combination of pharmaceutical products is one component in the combined product and a computer application is another.BACKGROUND[0003]Today pharmaceutical products on the market are powerful products solving health problems of the patients. However, most often the...

AI Technical Summary

Benefits of technology

The invention is a combination product that integrates multiple pharmaceutical products through a customized question-feedback model (QFM) that improves the treatment of patients by enhancing clinical effect, safety, and quality of life, compared to using just the individual pharmaceutical products alone. The QFM is developed based on the clinical characteristics of each pharmaceutical product and the patient's circumstances. The QAM evaluates the patient's health situation continuously, and provides feedback to the patient and healthcare personnel to improve the clinical effect, safety, or quality of life. The objective is to use the type of feedback that achieves the best clinical effect for each patient. Overall, the invention optimizes and individualizes the use of each pharmaceutical product in the combination to achieve improved clinical effect, safety, and quality of life for patients.

Problems solved by technology

However, most often they solve just a specific problem or symptom of the patient, i.e. a limited part of the patient needs; meanwhile the patient experiences a wider complex situation with several other issues and symptoms due to their illness.

A lot of drugs interact with each other often causing negative health effects for the patients and sometimes critical situations.

Today a lot of patients are forced to emergency healthcare visits due to unsuitable medication.

Today drugs on the market are thoroughly tested with regard to their clinical affect and safety during extensive clinical trials before they are approved for marketing by a national or regional Medical Products Agency, such as EMA in Europe or FDA in the U.S. In most cases, however, there are no verifications, or clinical trials, evaluating the situation of the patients in real clinical practice concerning the situation that several patients are taking a mix of multiple pharmaceuticals.

This information is often available for several different actors to utilize for researching purposes, but not effectively available directly to the individual patient using the drug.

Today drugs in clinical practice are not possible to individualize to the circumstances of each specific patient.

There is seldom any follow-up of the results of the specific patient in clinical practice, and if the patient not themselves responds in any way to the results of the medication, no action is done to improve or secure the result of the treatment.

The guidance for matching patient specific conditions to the use of pharmaceutical products is limited.

Due to the lack of adherence to medication the results of pharmaceutical treatments in clinical practice have difficulties in reaching similar results of clinical effect as the ones made in clinical trials during the development of the pharmaceutical products.

In clinical practice, however, this is difficult to achieve and the patient is mainly responsible with little or no support to accomplish it properly.

Images